Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genome-derived vaccines.

Anne S De Groot1, Rino Rappuoli

  • 1TB/HIV Research Laboratory, Brown University, Providence, RI 20903, USA. Anne_DeGroot@Brown.edu

Expert Review of Vaccines
|February 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.

Human vaccines & immunotherapeutics·2026
Same author

HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.

The AAPS journal·2026
Same author

Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products.

Frontiers in immunology·2025
Same author

Establishment of Immune Biobank for Vaccine Immunogenicity Prediction Using In Vitro and In Silico Methods Against Porcine Reproductive and Respiratory Syndrome Virus.

Vaccines·2025
Same author

A method for identifying neoantigens through isolation of circulating tumor cells using apheresis among patients with advanced-stage cancer.

Frontiers in immunology·2025
Same author

T cell epitope content comparison using EpiCC correlates with vaccine efficacy against heterologous porcine reproductive and respiratory syndrome virus type 2 strains.

Frontiers in microbiology·2025
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Genome sequencing accelerates vaccine development by identifying novel antigens. This technology, combined with computational immunology, is paving the way for next-generation vaccines targeting specific T- and B-cell epitopes.

Area of Science:

  • Microbial genomics
  • Vaccinology
  • Computational immunology

Background:

  • The publication of the first pathogenic bacterial genome in 1995 revolutionized vaccine research.
  • Over 97 bacterial pathogens have been sequenced, with 110+ projects ongoing, demonstrating rapid advancement in genomic capabilities.
  • High-throughput sequencing now allows microbial genome drafting in 1-2 days.

Purpose of the Study:

  • To explore the convergence of microbial genome sequencing, computational immunology, and vaccine technologies.
  • To highlight the shift towards genome mining for novel vaccine antigen discovery.
  • To project the future development of next-generation vaccines based on predicted epitopes.

Main Methods:

  • Utilizing microarrays, immunoinformatics, proteomics, and high-throughput immunology assays.

Related Experiment Videos

  • Analyzing vast amounts of genomic data to identify potential vaccine targets.
  • Genome mining to discover novel antigens and engineer T- and B-cell epitopes.

    • Main Results:

    • Novel antigens discovered through genome mining are currently in clinical trials.
    • Anticipation of a new class of vaccines composed of genome-predicted, assembled, and engineered T- and B-cell epitopes within five years.
    • Demonstration of the feasibility and acceleration of vaccine development through genomic approaches.

    Conclusions:

    • The integration of microbial genomics, computational immunology, and advanced vaccine technologies is transforming vaccine research.
    • Genome mining is emerging as a central strategy for identifying and developing innovative vaccine candidates.
    • Future vaccines will likely be precisely engineered based on genomic and immunological data.